Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Murugesan, 2022

tofacitinib (n=50) vs. standard of care (n=50)

randomized controlled trial   risk of bias NA

Studied treatment

Control treatment

Patients

COVID-19 mild to moderate

Method

Remark